Znanstveni rad - Izvorni znanstveni rad
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
European Journal of Preventive Cardiology, 28 (2021), 1; 33-43. https://doi.org/10.1177/2047487320941987

(ODYSSEY OUTCOMES Committees and Investigators) Diaz, Rafael; Li, Qian H; Bhatt, Deepak L; Bittner, Vera A; Baccara-Dinet, Marie T; Goodman, Shaun G; Jukema, J Wouter; Kimura, Takeshi; Parkhomenko, Alexander; Pordy, Robert; Reiner, Željko; Roe, Matthew T; Szarek, Michael; Tse, Hung-Fat; White, Harvey D; Zahger, Doron; Zeiher, Andreas M; Schwartz, Gregory G; Steg, Ph Gabriel Više autora...

Citirajte ovaj rad

Diaz, R., Li, Q. H., Bhatt, D. L., Bittner, V. A., Baccara Dinet, M. T., Goodman, S. G. ... Steg, P. G. (2021). Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology, 28. (1), 33-43. doi: 10.1177/2047487320941987

Diaz, Rafael, et al. "Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial." European Journal of Preventive Cardiology, vol. 28, br. 1, 2021, str. 33-43. https://doi.org/10.1177/2047487320941987

Diaz, Rafael, Qian H Li, Deepak L Bhatt, Vera A Bittner, Marie T Baccara Dinet, Shaun G Goodman, J Wouter Jukema, et al. "Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial." European Journal of Preventive Cardiology 28, br. 1 (2021): 33-43. https://doi.org/10.1177/2047487320941987

Diaz, R., et al. (2021) 'Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial', European Journal of Preventive Cardiology, 28(1), str. 33-43. doi: 10.1177/2047487320941987

Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara Dinet MT, Goodman SG, i sur.. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology [Internet]. 23.03.2021. [pristupljeno 04.07.2022.];28(1):33-43. doi: 10.1177/2047487320941987

R. Diaz, et al., "Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial", European Journal of Preventive Cardiology, vol. 28, br. 1, str. 33-43, Ožujak 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:183800. [Citirano: 04.07.2022.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.